(NasdaqGM:NTLA), CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2025, it awarded inducement grants to three new employees under Intellia's 2024 Inducement Plan as a material inducement to employment. The inducement grants […]

(NasdaqGM:HIFS), HINGHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) — HINGHAM INSTITUTION FOR SAVINGS (NASDAQ:HIFS) (“the Bank”), Hingham, Massachusetts, announced that its Board of Directors has authorized a share repurchase program (“the Program”) pursuant to which the Bank may repurchase up to $20 million of its outstanding common stock, having received all regulatory approvals as may

(NasdaqGM:NAMS),(NasdaqGM:NAMSW), NAARDEN, The Netherlands and MIAMI, Dec. 05, 2025 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or

(NasdaqGM:KYMR), Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BroADen Phase

Announcement relating to despatch of Rule 15 proposal GlobeNewswire December 05, 2025 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 15(C) OF

Parsons Selected for $1B Sound Transit MATOC to Support Regional Transit Expansion GlobeNewswire December 05, 2025 CHANTILLY, Va., Dec. 05, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced the company has secured a position on Sound Transit's 2025 $1 billion ceiling Multiple Award Task Order Contract (MATOC) for design services. This five-year contract, with

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire December 05, 2025 CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2025, it awarded inducement grants to three new employees under

Hingham Savings Authorizes Stock Repurchase Program GlobeNewswire December 05, 2025 HINGHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) — HINGHAM INSTITUTION FOR SAVINGS (NASDAQ:HIFS) (“the Bank”), Hingham, Massachusetts, announced that its Board of Directors has authorized a share repurchase program (“the Program”) pursuant to which the Bank may repurchase up to $20 million of its outstanding

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire December 05, 2025 NAARDEN, The Netherlands and MIAMI, Dec. 05, 2025 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 GlobeNewswire December 05, 2025 Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing